Share on LinkedInShare on LinkedIn

ARTICLE · 17 JUNE 2026

Lessons Learned: When A Non-Traditional Innovator Defends Genus-Level Biologic Patents

A recent Federal Circuit decision offers a significant reaffirmation of patent protection for method-of-use claims in the biologics space. Notably, the patent holder in this case was not a traditional brand innovator but a company more commonly associated with generic drug manufacturing — one that had developed its own proprietary biologic and successfully defended it against an established innovator challenger.

United StatesIntellectual Property

Key Takeaways from a Recent Federal Circuit Ruling on Method-of-Use Claims and Written Description in Biologics

Overview

A recent Federal Circuit decision offers a significant reaffirmation of patent protection for method-of-use claims in the biologics space. Notably, the patent holder in this case was not a traditional brand innovator but a company more commonly associated with generic drug manufacturing — one that had developed its own proprietary biologic and successfully defended it against an established innovator challenger. The ruling reinforces that the legal framework for genus-level patent protection remains robust when claims are properly structured, and it offers practical lessons for any organization building or defending an innovator portfolio.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from